Dexmedetomidine Overdose in the Perioperative Setting

Annals of Pharmacotherapy

Volumn 38, Issue 5, 2004, Pages 803-807

  Jorden, Victor S B ^a,b   Pousman, Robert M ^c   Sanford, Mary M ^d   Thorborg, Per A J ^e   Hutchens, Michael P ^e  

^a ABBOTT LABORATORIES   (United States)

^b ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d CATHOLIC MEDICAL CENTER   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Dexmedetomidine; Overdose

Indexed keywords

DEXMEDETOMIDINE; FENTANYL; GLYCERYL TRINITRATE; MORPHINE; NITROPRUSSIDE SODIUM; PROPOFOL;

ADRENERGIC ACTIVITY; ADULT; AGED; ANESTHESIA INDUCTION; ARTICLE; CASE REPORT; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG OVERDOSE; HEMODYNAMIC MONITORING; HEMODYNAMIC PARAMETERS; HOSPITALIZATION; HUMAN; HYPERTENSION; INFUSION; MALE; PERIOPERATIVE PERIOD; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SEDATION; TITRIMETRY; TREATMENT WITHDRAWAL; VASOCONSTRICTION;

ADRENERGIC ALPHA-AGONISTS; ADULT; AGED; DEXMEDETOMIDINE; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MEDICATION ERRORS; MIDDLE AGED; OVERDOSE; PERIOPERATIVE CARE;

EID: 1942502909     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1D376     Document Type: Article

References (28)

1. Package insert. Dexmedetomidine (dexmedetomidine HCl). Abbott Park, IL: Abbott Laboratories, Inc., February 2001.
2. 2-adrenoreceptor agonist dexmedetomidine in postsurgical sedation in the intensive care unit. J Intensive Care Med 2003;18:29-41.
3. Venn RM, Newman PJ, Grounds RM. A Phase II study to evaluate the efficacy of dexmedetomidine for sedation in the medical intensive care unit. Intensive Care Med 2003;29:201-7.
4. Arain SR, Ebert TJ. The efficacy, side effects, and recovery characteristics of dexmedetomidine versus propofol when used for intraoperative sedation. Anesth Analg 2002;95:461-6.
5. Jalonen J, Hynynen M, Kuitunen A, Heikkila H, Perttila J, Salmenpera M, et al. Dexmedetomidine as an anesthetic adjunct in coronary artery bypass grafting. Anesthesiology 1997;86:331-45.
6. Kohn LT, Corrigan JM, Donaldson MS, eds. To err is human, building a safer health system. Committee on Quality of Health Care in America, Institute of Medicine. Washington, DC: National Academies Press, 2000.
7. Van dem Bemt PM, Fijn R, van der Voort PH, Gossen AA, Egberts TC, Brouwers JR. Frequency and determinants of drug administration errors in the intensive care unit. Crit Care Med 2002;30:846-50.
8. Cullen DJ, Sweitzer BJ, Bates DW, Burdick E, Edmondson A, Leape LL. Preventable adverse drug events in hospitalized patients: a comparative study of intensive care and general units. Crit Care Med 1997;25:1289-97.
9. Karch AM, Karch FE. The naked decimal point. And eight other common errors that can be avoided. Am J Nurs 2001;101:22.
10. Kamibayashi T, Maze M. Clinical uses of alpha-2 agonists. Anesthesiology 2000;93:1345-9.
11. Litovitz TL, Klein-Schwartz W, Rodgers GC, Cobaugh DJ, Youniss J, Omslaer JC, et al. 2001 Annual Report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2002;20:391-452.
12. Klein-Schwartz W. Trends and toxic effects from pediatric clonidine exposures. Arch Pediatr Adolesc Med 2002;156:392-6.
13. Romano MJ, Dinh A. A 1000-fold overdose of clonidine caused by a compounding error in a 5-year-old child with attention-deficit/hyperactivity disorder. Pediatrics 2001;108:471-2.
14. Frye CB, Vance MA. Hypertensive crisis and myocardial infarction following massive clonidine overdose. Ann Pharmacother 2000;34:611-5. DOI 10.1345/aph.19257
15. Anderson RJ, Hart GR, Crumpler CP, Lerman MJ. Clonidine overdose: report of six cases and review of the literature. Ann Emerg Med 1981;10:107-12.
16. Zarifis J, Lip GY, Ferner RE. Poisoning with anti-hypertensive drugs: methyldopa and clonidine. J Hum Hypertens 1995;9:787-90.
17. Roberge RJ, McGuire SP, Krenzelok EP. Yohimbine as an antidote for clonidine overdose. Am J Emerg Med 1996;14:678-80.
18. Bertoli M. Clonidine removal by hemoperfusion in a uremic patient. Nephron 1996;72:117-8.
19. Bloor BC, Ward DS, Belleville JP, Maze M. Effects of intravenous dexmedetomidine in humans. II. Hemodynamic changes. Anesthesiology 1992;77:1134-42.
20. Belleville JP, Ward DS, Bloor BC, Maze M. Effects of intravenous dexmedetomidine in humans. I. Sedation, ventilation, and metabolic rate. Anesthesiology 1992;77:1125-33.
21. Ebert TJ, Hall JE, Barney JA, Uhrich TD, Colinco MD. The effects of increasing plasma concentrations of dexmedetomidine in humans. Anesthesiology 2000;93:382-94.
22. Jorden V, Tung A. Dexmedetomidine: clinical update. Semin Anesth Periop Med Pain 2002;21:265-74.
23. Herr DL, Sum-Ping STJ, England M. ICU sedation after coronary artery bypass graft surgery: dexmedetomidine-based versus propofol-based sedation regimens. J Cardiothorac Vasc Anesth 2003;17:576-84.
24. Talke P, Chen R, Thomas B, Aggarwall A, Gottlieb A, Thorborg P, et al. The hemodynamic and adrenergic effects of perioperative dexmedetomidine infusion after vascular surgery. Anesth Analg 2000;90:834-9.
25. McCallum JB, Boban N, Hogan Q, Schmeling WT, Kampine JP, Bosnja ZJ. The mechanism of alpha-2-adrenergic inhibition of sympathetic ganglionic transmission. Anesth Analg 1998;87:503-10.
26. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
27. Aantaa R, Jaakola ML, Kallio A, Kanto J. Reduction of the minimum alveolar concentration of isoflurane by dexmedetomidine. Anesthesiology 1997;86:1055-60.
28. Venn RM, Karol MD, Grounds RM. Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive care. Br J Anaesth 2002;88:669-75.